Zomedica Pharmaceuticals Operating Margin vs. EBITDA
| ZOM Stock | USD 0.13 0.00 0.00% |
Zomedica Pharmaceuticals Operating Profit Margin |
|
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.79 | 0.6876 |
|
|
For Zomedica Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Zomedica Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Zomedica Pharmaceuticals Corp utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Zomedica Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Zomedica Pharmaceuticals Corp over time as well as its relative position and ranking within its peers.
Zomedica |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zomedica Pharmaceuticals. If investors know Zomedica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zomedica Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.06) | Revenue Per Share 0.027 | Quarterly Revenue Growth 0.018 | Return On Assets (0.09) | Return On Equity (0.24) |
The market value of Zomedica Pharmaceuticals is measured differently than its book value, which is the value of Zomedica that is recorded on the company's balance sheet. Investors also form their own opinion of Zomedica Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Zomedica Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zomedica Pharmaceuticals' market value can be influenced by many factors that don't directly affect Zomedica Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zomedica Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zomedica Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zomedica Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Zomedica Pharmaceuticals EBITDA vs. Operating Margin Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Zomedica Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Zomedica Pharmaceuticals value to that of its competitors to determine the firm's financial worth. Zomedica Pharmaceuticals Corp is rated below average in operating margin category among its peers. It is rated below average in ebitda category among its peers . At this time, Zomedica Pharmaceuticals' Operating Profit Margin is very stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Zomedica Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Zomedica EBITDA vs. Operating Margin
Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Zomedica Pharmaceuticals |
| = | (1.48) % |
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Zomedica Pharmaceuticals |
| = | (29.39 M) |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Zomedica EBITDA Comparison
Zomedica Pharmaceuticals is currently under evaluation in ebitda category among its peers.
Zomedica Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Zomedica Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Zomedica Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Zomedica Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Zomedica Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 48 K | 59.2 K | |
| Operating Income | -31.6 M | -30 M | |
| Income Before Tax | -35.9 M | -34.1 M | |
| Net Loss | -34.5 M | -32.8 M | |
| Net Loss | -14.9 M | -15.7 M | |
| Total Other Income Expense Net | -4.3 M | -4.1 M | |
| Net Loss | -15.3 M | -16.1 M | |
| Income Tax Expense | -1.3 M | -1.3 M | |
| Interest Income | 5.6 M | 5.9 M | |
| Non Operating Income Net Other | -142.2 K | -149.3 K | |
| Net Interest Income | 5.4 M | 5.7 M | |
| Change To Netincome | 9.1 M | 9.5 M | |
| Net Loss | (0.04) | (0.04) | |
| Income Quality | 0.46 | 0.87 | |
| Net Income Per E B T | 0.96 | 1.05 |
Zomedica Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Zomedica Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Zomedica Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Zomedica Pharmaceuticals' important profitability drivers and their relationship over time.
Use Zomedica Pharmaceuticals in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Zomedica Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Zomedica Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Zomedica Pharmaceuticals Pair Trading
Zomedica Pharmaceuticals Corp Pair Trading Analysis
The ability to find closely correlated positions to Zomedica Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Zomedica Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Zomedica Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Zomedica Pharmaceuticals Corp to buy it.
The correlation of Zomedica Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Zomedica Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Zomedica Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Zomedica Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Zomedica Pharmaceuticals position
In addition to having Zomedica Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Real Estate Thematic Idea Now
Real Estate
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Real Estate theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Real Estate Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Your Current Watchlist. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
To fully project Zomedica Pharmaceuticals' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Zomedica Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Zomedica Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows.